Association of Gestational Weight Gain With Adverse Maternal and Infant Outcomes.
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
07 05 2019
07 05 2019
Historique:
entrez:
8
5
2019
pubmed:
8
5
2019
medline:
29
5
2019
Statut:
ppublish
Résumé
Both low and high gestational weight gain have been associated with adverse maternal and infant outcomes, but optimal gestational weight gain remains uncertain and not well defined for all prepregnancy weight ranges. To examine the association of ranges of gestational weight gain with risk of adverse maternal and infant outcomes and estimate optimal gestational weight gain ranges across prepregnancy body mass index categories. Individual participant-level meta-analysis using data from 196 670 participants within 25 cohort studies from Europe and North America (main study sample). Optimal gestational weight gain ranges were estimated for each prepregnancy body mass index (BMI) category by selecting the range of gestational weight gain that was associated with lower risk for any adverse outcome. Individual participant-level data from 3505 participants within 4 separate hospital-based cohorts were used as a validation sample. Data were collected between 1989 and 2015. The final date of follow-up was December 2015. Gestational weight gain. The main outcome termed any adverse outcome was defined as the presence of 1 or more of the following outcomes: preeclampsia, gestational hypertension, gestational diabetes, cesarean delivery, preterm birth, and small or large size for gestational age at birth. Of the 196 670 women (median age, 30.0 years [quartile 1 and 3, 27.0 and 33.0 years] and 40 937 were white) included in the main sample, 7809 (4.0%) were categorized at baseline as underweight (BMI <18.5); 133 788 (68.0%), normal weight (BMI, 18.5-24.9); 38 828 (19.7%), overweight (BMI, 25.0-29.9); 11 992 (6.1%), obesity grade 1 (BMI, 30.0-34.9); 3284 (1.7%), obesity grade 2 (BMI, 35.0-39.9); and 969 (0.5%), obesity grade 3 (BMI, ≥40.0). Overall, any adverse outcome occurred in 37.2% (n = 73 161) of women, ranging from 34.7% (2706 of 7809) among women categorized as underweight to 61.1% (592 of 969) among women categorized as obesity grade 3. Optimal gestational weight gain ranges were 14.0 kg to less than 16.0 kg for women categorized as underweight; 10.0 kg to less than 18.0 kg for normal weight; 2.0 kg to less than 16.0 kg for overweight; 2.0 kg to less than 6.0 kg for obesity grade 1; weight loss or gain of 0 kg to less than 4.0 kg for obesity grade 2; and weight gain of 0 kg to less than 6.0 kg for obesity grade 3. These gestational weight gain ranges were associated with low to moderate discrimination between those with and those without adverse outcomes (range for area under the receiver operating characteristic curve, 0.55-0.76). Results for discriminative performance in the validation sample were similar to the corresponding results in the main study sample (range for area under the receiver operating characteristic curve, 0.51-0.79). In this meta-analysis of pooled individual participant data from 25 cohort studies, the risk for adverse maternal and infant outcomes varied by gestational weight gain and across the range of prepregnancy weights. The estimates of optimal gestational weight gain may inform prenatal counseling; however, the optimal gestational weight gain ranges had limited predictive value for the outcomes assessed.
Identifiants
pubmed: 31063572
pii: 2732571
doi: 10.1001/jama.2019.3820
pmc: PMC6506886
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1702-1715Subventions
Organisme : British Heart Foundation
ID : RG/15/17/31749
Pays : United Kingdom
Organisme : NIEHS NIH HHS
ID : K12 ES019852
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES023513
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS047537
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES001247
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA096525
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK103246
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_12011/4
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R01 HD034568
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00011/6
Pays : United Kingdom
Organisme : FIC NIH HHS
ID : R03 TW007152
Pays : United States
Organisme : Medical Research Council
ID : MC_UP_A620_1017
Pays : United Kingdom
Organisme : NIH HHS
ID : UG3 OD023286
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Acta Paediatr Suppl. 2006 Apr;450:76-85
pubmed: 16817681
Obstet Gynecol. 2007 Oct;110(4):745-51
pubmed: 17906004
Obstet Gynecol. 2007 Oct;110(4):752-8
pubmed: 17906005
Obstet Gynecol. 2007 Oct;110(4):759-64
pubmed: 17906006
Bull World Health Organ. 2007 Sep;85(9):660-7
pubmed: 18026621
Matern Child Health J. 2011 Oct;15(7):860-5
pubmed: 18247109
Am J Epidemiol. 2009 Jul 15;170(2):173-80
pubmed: 19439579
Acta Paediatr Scand. 1991 Aug-Sep;80(8-9):756-62
pubmed: 1957592
Am J Clin Nutr. 2009 Dec;90(6):1552-8
pubmed: 19812177
Am J Clin Nutr. 2011 Nov;94(5):1225-31
pubmed: 21918221
Health Technol Assess. 2012 Jul;16(31):iii-iv, 1-191
pubmed: 22814301
PLoS One. 2013 Apr 16;8(4):e61627
pubmed: 23613888
Obes Rev. 2014 Apr;15(4):338-47
pubmed: 24321007
BMJ. 2014 Feb 10;348:g1285
pubmed: 24513442
JAMA. 2014 Apr 16;311(15):1536-46
pubmed: 24737366
Am J Clin Nutr. 2014 Aug;100(2):701-7
pubmed: 24965305
Lancet Diabetes Endocrinol. 2015 Oct;3(10):767-77
pubmed: 26165396
Eur J Epidemiol. 2015 Nov;30(11):1141-52
pubmed: 26377700
JAMA. 2017 Jun 6;317(21):2207-2225
pubmed: 28586887
BMJ. 2017 Jul 19;358:j3119
pubmed: 28724518
Lancet Child Adolesc Health. 2018 Nov;2(11):812-821
pubmed: 30201470
BMC Med. 2018 Nov 5;16(1):201
pubmed: 30396358
Gynecol Obstet Invest. 1998;46(1):9-16
pubmed: 9692334